help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fahy, J. V.
Right arrow Articles by Boushey, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fahy, J. V.
Right arrow Articles by Boushey, H. A.

Am. J. Respir. Crit. Care Med., Vol 155, No. 6, Jun 1997, 1828-1834.

The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects

JV Fahy, HE Fleming, HH Wong, JT Liu, JQ Su, J Reimann, RB Fick Jr and HA Boushey
Cardiovascular Research Institute and the Department of Medicine, University of California, San Francisco, USA.

A humanized murine monoclonal antibody directed to the Fc epsilonR1- binding domain of human IgE (rhuMAb-E25) has been shown to inhibit the binding of IgE to mast cells without provoking mast cell activation. To examine the effects of neutralizing IgE on allergic airway responses, we assessed the effects of 9 wk of treatment with rhuMAb-E25 in a parallel group, randomized, double-blind, placebo-controlled study of 19 allergic asthmatic subjects. We found that treatment with rhuMAb-E25 reduced serum IgE, increased the dose of allergen needed to provoke an early asthmatic response, reduced the mean maximal fall in FEV1 during the early response (30 +/- 10% at baseline to 18.8 +/- 8%, versus 33 +/- 8% at baseline to 34 +/- 4% after placebo; p = 0.01), and reduced the mean maximal fall in FEV1 during the late response (24 +/- 20% at baseline to 9 +/- 10% versus 20 +/- 17% at baseline to 18 +/- 17% after placebo; p = 0.047). We conclude that an anti-IgE monoclonal antibody, which inhibits binding of IgE to its receptor, suppresses the early- and late-phase responses to inhaled allergen in allergic asthmatic subjects. Targeting IgE with rhuMAb-E25 might be a useful treatment for allergic asthma.


This article has been cited by other articles:


Home page
 ERRHome page
J. Bousquet, U. Wahn, E. O. Meltzer, H. Fox, S. Hedgecock, K. Thomas, and A. Fowler-Taylor
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
Eur. Respir. Rev., April 1, 2008; 17(107): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. A. Hanania
Targeting Airway Inflammation in Asthma: Current and Future Therapies
Chest, April 1, 2008; 133(4): 989 - 998.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
E. Hamelmann
The rationale for treating allergic asthma with anti-IgE
Eur. Respir. Rev., September 1, 2007; 16(104): 61 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. M. Gauvreau, E. M. Hessel, L.-P. Boulet, R. L. Coffman, and P. M. O'Byrne
Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 15 - 20.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. C. Strunk and G. R. Bloomberg
Omalizumab for asthma.
N. Engl. J. Med., June 22, 2006; 354(25): 2689 - 2695.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. D. Kraneveld, M. Kool, A. H. van Houwelingen, P. Roholl, A. Solomon, D. S. Postma, F. P. Nijkamp, and F. A. Redegeld
From The Cover: Elicitation of allergic asthma by immunoglobulin free light chains
PNAS, February 1, 2005; 102(5): 1578 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Djukanovic, S. J. Wilson, M. Kraft, N. N. Jarjour, M. Steel, K. F. Chung, W. Bao, A. Fowler-Taylor, J. Matthews, W. W. Busse, et al.
Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 583 - 593.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. A Davis
Omalizumab: A Novel Therapy for Allergic Asthma
Ann. Pharmacother., July 1, 2004; 38(7): 1236 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
S.T. Holgate
Lessons learnt from the epidemic of asthma
QJM, May 1, 2004; 97(5): 247 - 257.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. C. Grootendorst and K. F. Rabe
Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2004; 1(2): 77 - 87.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. E. Silkoff, F. A. Romero, N. Gupta, R. G. Townley, and H. Milgrom
Exhaled Nitric Oxide in Children With Asthma Receiving Xolair (Omalizumab), a Monoclonal Anti-Immunoglobulin E Antibody
Pediatrics, April 1, 2004; 113(4): e308 - e312.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Hanf, O. Noga, A. O'Connor, and G. Kunkel
Omalizumab inhibits allergen challenge-induced nasal response
Eur. Respir. J., March 1, 2004; 23(3): 414 - 419.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Sehra, G. Pynaert, K. Tournoy, A. Haegeman, P. Matthys, Y. Tagawa, R. Pauwels, and J. Grooten
Airway IgG Counteracts Specific and Bystander Allergen-Triggered Pulmonary Inflammation by a Mechanism Dependent on Fc{gamma}R and IFN-{gamma}
J. Immunol., August 15, 2003; 171(4): 2080 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. J. Holtzman
Drug Development for Asthma
Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 163 - 171.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Nowak-Wegrzyn
Future Approaches to Food Allergy
Pediatrics, June 1, 2003; 111(6): 1672 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. Al-Muhsen, A. E. Clarke, and R. S. Kagan
Peanut allergy: an overview
Can. Med. Assoc. J., May 13, 2003; 168(10): 1279 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. L. Aitken, K. E. Greene, M. R. Tonelli, J. L. Burns, J. C. Emerson, C. H. Goss, and R. L. Gibson
Analysis of Sequential Aliquots of Hypertonic Saline Solution-Induced Sputum From Clinically Stable Patients With Cystic Fibrosis
Chest, March 1, 2003; 123(3): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. A. Boushey
New and Exploratory Therapies for Asthma
Chest, March 1, 2003; 123(2007): 439S - 445S.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
H Milgrom
Is there a role for treatment of asthma with omalizumab?
Arch. Dis. Child., January 1, 2003; 88(1): 71 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Buhl, G. Hanf, M. Soler, G. Bensch, J. Wolfe, F. Everhard, K. Champain, H. Fox, and J. Thirlwell
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
Eur. Respir. J., November 1, 2002; 20(5): 1088 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Buhl, M. Soler, J. Matz, R. Townley, J. O'Brien, O. Noga, K. Champain, H. Fox, J. Thirlwell, and G. Della Cioppa
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Eur. Respir. J., July 1, 2002; 20(1): 73 - 78.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J Douwes, P Gibson, J Pekkanen, and N Pearce
Non-eosinophilic asthma: importance and possible mechanisms
Thorax, July 1, 2002; 57(7): 643 - 648.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, M. Watrous, M. McAlary, A. Fowler-Taylor, A. Racine, N. Gupta, et al.
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial
JAMA, December 19, 2001; 286(23): 2956 - 2967.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. S. SCHULMAN
Development of a Monoclonal Anti-Immunoglobulin E Antibody (Omalizumab) for the Treatment of Allergic Respiratory Disorders
Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): S6 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. W. BUSSE
Anti-Immunoglobulin E (Omalizumab) Therapy in Allergic Asthma
Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): S12 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Chanez
Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations
Eur. Respir. J., August 1, 2001; 18(2): 249 - 250.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, and G. Della Cioppa
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Eur. Respir. J., August 1, 2001; 18(2): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, M. McAlary, A. F. Taylor, and P. Rohane
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Pediatrics, August 1, 2001; 108 (2): e36 - e36.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. G. Woodruff and J. V. Fahy
Asthma: Prevalence, Pathogenesis, and Prospects for Novel Therapies
JAMA, July 25, 2001; 286(4): 395 - 398.
[Full Text] [PDF]

Home page
 ThoraxHome page
N R Henig, M R Tonelli, M V Pier, J L Burns, and M L Aitken
Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis
Thorax, April 1, 2001; 56(4): 306 - 311.
[Abstract] [Full Text]

Home page
 NEJMHome page
W. W. Busse and R. F. Lemanske
Asthma
N. Engl. J. Med., February 1, 2001; 344(5): 350 - 362.
[Full Text] [PDF]

Home page
 NEJMHome page
A.B. Kay
Allergy and Allergic Diseases- Second of Two Parts
N. Engl. J. Med., January 11, 2001; 344(2): 109 - 113.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. J. COYLE, C. M. LLOYD, and J.-C. GUTIERREZ-RAMOS
Biotherapeutic Targets for the Treatment of Allergic Airway Disease
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): S179 - 184.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. C. AVILA, M. R. SEGAL, H. H. WONG, H. A. BOUSHEY, and J. V. FAHY
Predictors of Late Asthmatic Response . Logistic Regression and Classification Tree Analyses
Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 2092 - 2095.
[Abstract] [Full Text]

Home page
 NEJMHome page
S. S. Salvi, K. S. Babu, H. Milgrom, R. B. Fick, and W. J. Metzger
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
N. Engl. J. Med., April 27, 2000; 342(17): 1292 - 1293.
[Full Text]

Home page
 NEJMHome page
H. Milgrom, R. B. Fick, J. Q. Su, J. D. Reimann, R. K. Bush, M. L. Watrous, W. J. Metzger, and The rhuMAb-E25 Study Group
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
N. Engl. J. Med., December 23, 1999; 341(26): 1966 - 1973.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Barnes
Anti-IgE Antibody Therapy for Asthma
N. Engl. J. Med., December 23, 1999; 341(26): 2006 - 2008.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. V. FAHY, D. W. COCKCROFT, L.-P. BOULET, H. H. WONG, F. DESCHESNES, E. E. DAVIS, J. RUPPEL, J. Q. SU, and D. C. ADELMAN
Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects
Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 1023 - 1027.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
R. J. J. van Neerven, T. Wikborg, G. Lund, B. Jacobsen, A. Brinch-Nielsen, J. Arnved, and H. Ipsen
Blocking Antibodies Induced by Specific Allergy Vaccination Prevent the Activation of CD4+ T Cells by Inhibiting Serum-IgE-Facilitated Allergen Presentation
J. Immunol., September 1, 1999; 163(5): 2944 - 2952.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Sur, J. S. Wild, B. K. Choudhury, N. Sur, R. Alam, and D. M. Klinman
Long Term Prevention of Allergic Lung Inflammation in a Mouse Model of Asthma by CpG Oligodeoxynucleotides
J. Immunol., May 15, 1999; 162(10): 6284 - 6293.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. S. Saini, D. W. MacGlashan Jr., S. A. Sterbinsky, A. Togias, D. C. Adelman, L. M. Lichtenstein, and B. S. Bochner
Down-Regulation of Human Basophil IgE and FC{epsilon}RI{alpha} Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo
J. Immunol., May 1, 1999; 162(9): 5624 - 5630.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. F. RABE
Mechanisms of Immune Sensitization of Human Bronchus
Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S161 - S170.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society